Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-cash Items (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Non-cash Items for 4 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 113.48% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, up 113.48% year-over-year, with the annual reading at $4.6 million for FY2025, 113.48% up from the prior year.
  • Non-cash Items for Q4 2025 was $4.6 million at Phathom Pharmaceuticals, up from $4.5 million in the prior quarter.
  • The five-year high for Non-cash Items was $15.3 million in Q4 2023, with the low at $1.4 million in Q2 2022.
  • Average Non-cash Items over 4 years is $4.2 million, with a median of $3.5 million recorded in 2023.
  • The sharpest move saw Non-cash Items skyrocketed 241.82% in 2023, then crashed 86.06% in 2024.
  • Over 4 years, Non-cash Items stood at $4.5 million in 2022, then surged by 241.82% to $15.3 million in 2023, then plummeted by 86.06% to $2.1 million in 2024, then soared by 113.48% to $4.6 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $4.6 million, $4.5 million, and $4.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.